Position of the Transparency Council – Livtencity (maribavir)

At its meeting on 9 September 2024, the Transparency Council adopted position No. 91/2024 on the evaluation of the drug Livtencity (maribavir) under the drug program: Treatment of patients with unresponsive or refractory cytomegalovirus (CMV) infection (ICD-10: B25.0, B25.1, B25.8, B25.9).

Publication of the position >>